Earlier this year, speaking at the World Economic Forum in Davos, Elon Musk remarked that he believes aging is “very solvable” and suggested that once scientists fully understand why we age, the answer may prove to be “something obvious.” Shortly afterward, Harvard geneticist and Life Biosciences co-founder Dr. David Sinclair responded on X, writing:

“Aging has a relatively simple explanation and is apparently reversible. Clinical trials begin shortly.”

When Musk replied, “ER-100?“, Sinclair answered simply:

“Yes.“

Although Musk has no involvement in Life Biosciences or the ER-100 clinical program, the brief exchange underscored how advances in longevity science are beginning to capture attention well beyond biotechnology circles.

From Aging Theory to Human Medicine: First Age Reversal Human Study Approved by the FDA

David Sinclair, Professor of Human Genetics at Harvard Medical School, has been studying longevity medicine focusing on epigenetics, which are chemical modifications around our DNA that can turn genes off, on, or modify the degree of DNA gene expression.  Importantly, epigenetic changes do NOT mutate our DNA.   

He began Life Biosciences’ and its lead candidate, ER-100, was approved by the Food and Drug Administration (FDA) this year to begin Phase 1 human safety trials.  A major regulatory milestone.  

Life Biosciences will begin treating optic neuropathies, prevalent in people 50 and older,  that can lead to vision loss if not managed.  The neuropathies include open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION). Both conditions damage retinal ganglion cells (RGCs), the neurons responsible for transmitting visual information from the eye to the brain. Once these cells are lost, they have little capacity to regenerate, leading to irreversible vision loss. Current therapies primarily slow disease progression rather than restore damaged tissue.

ER-100 takes a fundamentally different approach.

Rather than replacing cells or simply protecting surviving neurons, the therapy aims to restore cellular function by resetting the epigenetic programs that regulate gene expression. Importantly, this process does not alter the DNA sequence itself. Instead, it seeks to restore more youthful patterns of gene regulation that become disrupted with aging and injury.

The Science Behind Epigenetic Restoration

ER-100 is built on Life Biosciences’ Epigenetic Restoration platform, which uses controlled expression of three transcription factors—OCT4, SOX2, and KLF4 (collectively known as OSK). These factors are three of the four Yamanaka factors that famously demonstrated the ability to reprogram mature cells toward a more youthful state.

Unlike complete cellular reprogramming, which can erase cellular identity and carries substantial safety concerns, Life Biosciences employs a strategy known as partial epigenetic reprogramming. The goal is to rejuvenate cells while preserving their specialized function.

The therapy is delivered through an intravitreal injection directly into the eye, allowing localized treatment while minimizing systemic exposure. Gene expression is designed to be tightly controlled, an important feature intended to improve safety for this first-in-human study.

First Patient Dosed: Crossing the Threshold

Following FDA’s clearance to begin the Phase 1 trial, the next major milestone came in June 2026 when Life Biosciences announced that the first participant had been dosed with ER-100.

While the event represents only the beginning of a Phase 1 safety study, its symbolic importance extends far beyond ophthalmology. For the first time, a therapy specifically designed to restore epigenetic information associated with aging is being tested in humans.

David Sinclair, Ph.D., co-founder of Life Biosciences and Professor of Genetics at Harvard Medical School, described the moment as an important test of a central hypothesis in aging biology: that age-related dysfunction may result not solely from irreversible damage but also from the loss of epigenetic information that could potentially be restored.

Why the Eye Is the Ideal Starting Point

The eye offers several advantages for first-in-human gene therapy studies.

It is relatively isolated from the rest of the body, allowing localized delivery and monitoring. Physicians can directly visualize retinal structures using high-resolution imaging and assess treatment effects through well-established functional tests such as visual field assessments and retinal imaging.

Additionally, retinal ganglion cells are particularly vulnerable to age-related degeneration, making optic neuropathies an attractive initial target for therapies intended to restore neuronal function.

A Milestone for the Longevity Field

Although ER-100 is being developed for vision disorders, many researchers view the trial as a broader proof-of-concept for cellular rejuvenation therapies.

Success in demonstrating safety—and eventually efficacy—could influence the development of regenerative treatments for a wide range of age-related diseases affecting the nervous system and other organs. At the same time, experts emphasize that this remains an early-stage clinical trial, and it will take years of careful evaluation before conclusions can be drawn about clinical benefit.

Looking Ahead

The initiation of ER-100’s clinical program represents a significant scientific milestone rather than a clinical breakthrough—at least for now. The coming months will focus primarily on understanding safety, tolerability, and early biological signals.

Whether partial epigenetic reprogramming ultimately fulfills its promise remains an open question. But with FDA clearance secured and the first patient now treated, the field has crossed an important threshold.

For the first time, one of longevity science’s most ambitious ideas has moved from animal studies into human clinical investigation. The results of this trial will be watched closely—not only by ophthalmologists and gene therapy researchers, but by the broader scientific community exploring whether aging itself can one day become a modifiable biological process.

The Conversation Around Reversing Aging

The launch of ER-100’s first-in-human trial has reignited discussion about whether aging itself can eventually become a treatable biological process. While the scientific community remains appropriately cautious, interest in epigenetic reprogramming has spread well beyond academic laboratories.